Israeli dermatology firm Sol-Gel's Q2 revenue drops sharply on prior-year IP sale

SOL-GEL TECHNOLOGIES

20/08/2026 13:50

Overview
Israel dermatology firm's Q2 revenue fell sharply yr/yr due to prior-year IP sale
Q2 net loss and loss per share, reversing prior-year profit
Company's pivotal Phase 3 Gorlin syndrome trial on track for late Nov 2026 readout

Outlook
Sol-Gel expects top-line results from SGT-610 Phase 3 trial in late November 2026
Company expects cash resources to fund operations into Q1 2028
Enrollment for proof-of-concept study in high-frequency BCC expected to begin in October 2026

Result Drivers
PRIOR-YEAR IP SALE - Co said Q2 revenue decrease was mainly due to $16.7 mln from sale of IP under agreement with Mayne in prior-year quarter
LOWER R&D SPENDING - Co attributed decrease in R&D expenses to reduced clinical trial expenses related to SGT-610

Company press release: ID:nGNX3rGy9z

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$591,000
 
Q2 Loss Per Share
 
$1.13
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for SOL-GEL TECHNOLOGIES LTD. is $184.00, about 134.1% above its August 19 closing price of $78.59

Reuters Recommended Reads
Aug 18 - LEO Pharma buys worldwide dersimelagon rights for up to $435 million
Aug 19 - Hong Kong's Sisram Medical H1 profit falls on China injectables investments
Aug 18 - Switzerland's SKAN Group H1 net sales rise on Services & Consumables growth, acquisitions

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)